Suvretta Capital Management
Latest statistics and disclosures from Suvretta Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RPRX, BHVN, ACLX, Horizon Therapeutics, INSM, and represent 26.82% of Suvretta Capital Management's stock portfolio.
- Added to shares of these 10 stocks: MSFT (+$69M), CMG (+$37M), AMZN (+$37M), AMD (+$34M), RPRX (+$29M), LLY (+$21M), BCYC (+$20M), BSX (+$18M), GE (+$18M), APO (+$17M).
- Started 11 new stock positions in BNTC, LLY, ANAB, CMG, RCUS, TEVA, KVUE, SYRE, APO, BCYC. MSFT.
- Reduced shares in these 10 stocks: Chinook Therapeutics (-$67M), SQ (-$29M), TSM (-$24M), , CP (-$21M), , DFS (-$19M), PINS (-$18M), , .
- Sold out of its positions in Activision Blizzard, Aeglea Biotherapeutics, Benitec Biopharma, TECH, CP, CELH, CRL, Chinook Therapeutics, CEG, DFS. EW, EVR, GFL, GS, MRVL, MTD, ORIC, PINS, Reata Pharmaceuticals Inc Cl A, SQ, TSM, UNP, World Wrestling Entertainment, ACN.
- Suvretta Capital Management was a net buyer of stock by $105M.
- Suvretta Capital Management has $1.9B in assets under management (AUM), dropping by -1.05%.
- Central Index Key (CIK): 0001569064
Tip: Access up to 7 years of quarterly data
Positions held by Suvretta Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Suvretta Capital Management
Suvretta Capital Management holds 87 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Royalty Pharma Shs Class A (RPRX) | 6.0 | $111M | +34% | 4.1M | 27.14 |
|
Biohaven (BHVN) | 5.6 | $104M | +3% | 4.0M | 26.01 |
|
Arcellx Common Stock (ACLX) | 5.6 | $103M | 2.9M | 35.88 |
|
|
Horizon Therapeutics Pub L SHS | 4.9 | $91M | 786k | 115.69 |
|
|
Insmed Com Par $.01 (INSM) | 4.7 | $87M | +10% | 3.4M | 25.25 |
|
Meta Platforms Cl A (META) | 4.6 | $84M | +11% | 281k | 300.21 |
|
Amazon (AMZN) | 4.3 | $79M | +88% | 620k | 127.12 |
|
Advanced Micro Devices (AMD) | 3.9 | $72M | +87% | 697k | 102.82 |
|
Intra Cellular Therapies (ITCI) | 3.9 | $71M | +14% | 1.4M | 52.09 |
|
Microsoft Corporation (MSFT) | 3.7 | $69M | NEW | 218k | 315.75 |
|
Kura Oncology (KURA) | 3.6 | $67M | +4% | 7.3M | 9.12 |
|
Wynn Resorts (WYNN) | 2.3 | $43M | +54% | 460k | 92.41 |
|
Marinus Pharmaceuticals Com New (MRNS) | 2.3 | $42M | +28% | 5.2M | 8.05 |
|
89bio (ETNB) | 2.2 | $42M | +12% | 2.7M | 15.44 |
|
General Electric Com New (GE) | 2.1 | $39M | +82% | 351k | 110.55 |
|
NVIDIA Corporation (NVDA) | 2.1 | $39M | +14% | 89k | 434.99 |
|
Chipotle Mexican Grill (CMG) | 2.0 | $37M | NEW | 20k | 1831.83 |
|
Global Payments (GPN) | 1.8 | $33M | 285k | 115.39 |
|
|
Terns Pharmaceuticals (TERN) | 1.6 | $30M | +8% | 6.0M | 5.03 |
|
Cogent Biosciences (COGT) | 1.6 | $30M | +37% | 3.1M | 9.75 |
|
Las Vegas Sands (LVS) | 1.6 | $30M | -6% | 643k | 45.84 |
|
Eyepoint Pharmaceuticals Com New (EYPT) | 1.5 | $28M | 3.5M | 7.99 |
|
|
Oracle Corporation (ORCL) | 1.5 | $27M | -19% | 255k | 105.92 |
|
Fulcrum Therapeutics (FULC) | 1.4 | $25M | 5.7M | 4.44 |
|
|
Ultragenyx Pharmaceutical (RARE) | 1.3 | $24M | +25% | 680k | 35.65 |
|
Kalvista Pharmaceuticals (KALV) | 1.3 | $23M | +18% | 2.4M | 9.63 |
|
Rh (RH) | 1.2 | $21M | -2% | 81k | 264.36 |
|
Eli Lilly & Co. (LLY) | 1.1 | $21M | NEW | 39k | 537.13 |
|
Sutro Biopharma (STRO) | 1.1 | $20M | 5.9M | 3.47 |
|
|
Bicycle Therapeutics Sponsored Ads (BCYC) | 1.1 | $20M | NEW | 1.0M | 20.09 |
|
Zura Bio Class A Ord Shs (ZURA) | 1.0 | $19M | 2.9M | 6.60 |
|
|
Boston Scientific Corporation (BSX) | 1.0 | $19M | +1839% | 354k | 52.80 |
|
Prokidney Corp Class A Ord Shs (PROK) | 1.0 | $18M | +21% | 3.9M | 4.58 |
|
Capital One Financial (COF) | 1.0 | $18M | -8% | 182k | 97.05 |
|
Wells Fargo & Company (WFC) | 0.9 | $18M | 429k | 40.86 |
|
|
Apollo Global Mgmt (APO) | 0.9 | $17M | NEW | 192k | 89.76 |
|
Hilton Worldwide Holdings (HLT) | 0.9 | $17M | 114k | 150.18 |
|
|
Inflarx Nv (IFRX) | 0.9 | $17M | 5.7M | 2.98 |
|
|
McKesson Corporation (MCK) | 0.9 | $16M | +1951% | 38k | 434.85 |
|
Johnson & Johnson (JNJ) | 0.8 | $14M | +8% | 90k | 155.75 |
|
UnitedHealth (UNH) | 0.7 | $14M | +112% | 27k | 504.19 |
|
Sana Biotechnology (SANA) | 0.6 | $12M | +40% | 3.0M | 3.87 |
|
Agios Pharmaceuticals (AGIO) | 0.6 | $11M | 454k | 24.75 |
|
|
Arcus Biosciences Incorporated (RCUS) | 0.6 | $11M | NEW | 597k | 17.95 |
|
Mereo Biopharma Group Spon Ads (MREO) | 0.5 | $9.5M | 7.4M | 1.29 |
|
|
Anaptysbio Inc Common (ANAB) | 0.5 | $8.6M | NEW | 479k | 17.96 |
|
Kezar Life Sciences (KZR) | 0.5 | $8.5M | 7.2M | 1.19 |
|
|
Alvotech Ordinary Shares (ALVO) | 0.5 | $8.5M | -7% | 928k | 9.12 |
|
Sanofi Sponsored Adr (SNY) | 0.3 | $6.2M | 116k | 53.64 |
|
|
Elanco Animal Health (ELAN) | 0.3 | $6.0M | +22% | 537k | 11.24 |
|
Arcutis Biotherapeutics (ARQT) | 0.3 | $6.0M | +30% | 1.1M | 5.31 |
|
Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 0.3 | $5.1M | NEW | 497k | 10.20 |
|
Astrazeneca Sponsored Adr (AZN) | 0.3 | $4.8M | +96% | 71k | 67.72 |
|
Biontech Se Sponsored Ads (BNTX) | 0.2 | $4.5M | 41k | 108.64 |
|
|
Danaher Corporation (DHR) | 0.2 | $4.1M | 16k | 248.10 |
|
|
Thermo Fisher Scientific (TMO) | 0.2 | $3.7M | 7.3k | 506.17 |
|
|
Kenvue (KVUE) | 0.2 | $3.4M | NEW | 172k | 20.08 |
|
Pepgen (PEPG) | 0.1 | $2.5M | 487k | 5.08 |
|
|
Natera (NTRA) | 0.1 | $2.3M | 52k | 44.25 |
|
|
AmerisourceBergen (COR) | 0.1 | $2.2M | 13k | 179.97 |
|
|
Nurix Therapeutics (NRIX) | 0.1 | $2.2M | 281k | 7.86 |
|
|
Incyte Corporation (INCY) | 0.1 | $2.2M | 38k | 57.77 |
|
|
Akili Common Stock (AKLI) | 0.1 | $2.1M | 3.8M | 0.55 |
|
|
Abbott Laboratories (ABT) | 0.1 | $2.0M | 21k | 96.85 |
|
|
Aeglea Biotherapeutics Com New (SYRE) | 0.1 | $2.0M | NEW | 162k | 12.25 |
|
Protagonist Therapeutics (PTGX) | 0.1 | $1.8M | +33% | 108k | 16.68 |
|
Gilead Sciences (GILD) | 0.1 | $1.7M | 23k | 74.94 |
|
|
Molecular Partners Ads (MOLN) | 0.1 | $1.7M | 400k | 4.14 |
|
|
Galapagos Nv Spon Adr (GLPG) | 0.1 | $1.6M | 47k | 34.55 |
|
|
Iqvia Holdings (IQV) | 0.1 | $1.4M | 7.2k | 196.75 |
|
|
Argenx Se Sponsored Adr (ARGX) | 0.1 | $1.4M | -17% | 2.8k | 491.63 |
|
Medtronic SHS (MDT) | 0.1 | $1.4M | 18k | 78.36 |
|
|
Anthem (ELV) | 0.1 | $1.3M | 3.0k | 435.42 |
|
|
CVS Caremark Corporation (CVS) | 0.1 | $1.2M | 17k | 69.82 |
|
|
Illumina (ILMN) | 0.1 | $1.2M | 8.7k | 137.28 |
|
|
Stryker Corporation (SYK) | 0.1 | $1.2M | 4.4k | 273.27 |
|
|
Cigna Corp (CI) | 0.1 | $1.1M | 4.0k | 286.07 |
|
|
Intuitive Surgical Com New (ISRG) | 0.0 | $897k | 3.1k | 292.29 |
|
|
Waters Corporation (WAT) | 0.0 | $864k | 3.2k | 274.21 |
|
|
Avantor (AVTR) | 0.0 | $806k | 38k | 21.08 |
|
|
Sarepta Therapeutics (SRPT) | 0.0 | $734k | 6.1k | 121.22 |
|
|
Benitec Biopharma Com New (BNTC) | 0.0 | $617k | NEW | 204k | 3.02 |
|
Agilent Technologies Inc C ommon (A) | 0.0 | $558k | 5.0k | 111.82 |
|
|
Dex (DXCM) | 0.0 | $549k | 5.9k | 93.30 |
|
|
IDEXX Laboratories (IDXX) | 0.0 | $402k | 920.00 | 437.27 |
|
|
United Therapeutics Corporation (UTHR) | 0.0 | $307k | 1.4k | 225.87 |
|
|
Opy Acquisition Corp I *w Exp 09/22/202 | 0.0 | $2.0k | 73k | 0.03 |
|
Past Filings by Suvretta Capital Management
SEC 13F filings are viewable for Suvretta Capital Management going back to 2013
- Suvretta Capital Management 2023 Q3 filed Nov. 14, 2023
- Suvretta Capital Management 2023 Q2 filed Aug. 14, 2023
- Suvretta Capital Management 2023 Q1 filed May 15, 2023
- Suvretta Capital Management 2022 Q4 filed Feb. 14, 2023
- Suvretta Capital Management 2022 Q3 filed Nov. 14, 2022
- Suvretta Capital Management 2022 Q2 filed Aug. 15, 2022
- Suvretta Capital Management 2022 Q1 filed May 16, 2022
- Suvretta Capital Management 2021 Q4 filed Feb. 14, 2022
- Suvretta Capital Management 2021 Q3 restated filed Nov. 16, 2021
- Suvretta Capital Management 2021 Q3 filed Nov. 15, 2021
- Suvretta Capital Management 2021 Q3 amended filed Nov. 15, 2021
- Suvretta Capital Management 2021 Q2 filed Aug. 16, 2021
- Suvretta Capital Management 2021 Q1 filed May 17, 2021
- Suvretta Capital Management 2020 Q4 filed Feb. 16, 2021
- Suvretta Capital Management 2020 Q3 filed Nov. 16, 2020
- Suvretta Capital Management 2020 Q2 filed Aug. 14, 2020